Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis

The Fourth Affiliated Hospital of Zhejiang University School of Medicine · 2026
ClinicalTrials.gov · Datasets · License: Public Domain · 2026
Open Source ↗
non-small-cell-lung-cancernsclc
non-small cell lung cancer, egfr mutant advanced non-small cell lung cancer, nsclc, egfr-tki resistance, skb264, anlotinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 874729
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.